Vanguard Group Inc. Has $128.25 Million Stake in Artivion, Inc. $AORT

Vanguard Group Inc. boosted its stake in shares of Artivion, Inc. (NYSE:AORT) by 8.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,029,059 shares of the company’s stock after acquiring an additional 232,424 shares during the quarter. Vanguard Group Inc. owned 6.42% of Artivion worth $128,250,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its holdings in shares of Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after purchasing an additional 538 shares during the last quarter. State of Wyoming acquired a new position in Artivion in the third quarter valued at about $80,000. Tower Research Capital LLC TRC grew its stake in Artivion by 447.6% during the second quarter. Tower Research Capital LLC TRC now owns 5,410 shares of the company’s stock worth $168,000 after buying an additional 4,422 shares during the last quarter. Diversified Trust Co acquired a new stake in shares of Artivion during the third quarter worth approximately $200,000. Finally, Atria Investments Inc acquired a new stake in shares of Artivion during the second quarter worth approximately $244,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Insider Transactions at Artivion

In other Artivion news, CEO James P. Mackin sold 20,962 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $37.59, for a total transaction of $787,961.58. Following the transaction, the chief executive officer owned 780,031 shares in the company, valued at approximately $29,321,365.29. This trade represents a 2.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John E. Davis sold 3,773 shares of the company’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $37.59, for a total value of $141,827.07. Following the completion of the sale, the insider directly owned 190,943 shares of the company’s stock, valued at approximately $7,177,547.37. This trade represents a 1.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 92,984 shares of company stock valued at $3,492,115. Corporate insiders own 8.10% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on AORT. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Oppenheimer restated an “outperform” rating and set a $50.00 target price on shares of Artivion in a report on Friday, November 7th. Citizens Jmp raised their target price on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Finally, Canaccord Genuity Group decreased their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $48.97.

Artivion Trading Up 0.0%

AORT opened at $38.56 on Wednesday. The firm has a 50 day simple moving average of $41.59 and a 200 day simple moving average of $42.95. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $48.25. The company has a market cap of $1.85 billion, a price-to-earnings ratio of 192.81 and a beta of 1.60. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62.

Artivion (NYSE:AORT) last released its earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. The firm had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The business’s quarterly revenue was up 19.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current year.

Trending Headlines about Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Analysts maintain a constructive view — the consensus rating reported is “Moderate Buy,” and several firms have reiterated buy/outperform ratings and mid‑to‑high price targets, which can support demand for AORT shares. Artivion Receives Consensus Rating
• Positive Sentiment: Management will present virtually at the Oppenheimer Healthcare MedTech & Services Conference (fireside chat), giving the company a chance to update guidance, product progress or commercialization milestones — an event that often attracts buy‑side attention. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Institutional investors have been adding to positions (Invesco, Summit Partners, Goldman Sachs, Two Sigma among those increasing exposure), which can provide steady bid support and signal confidence from larger, professional investors. MarketBeat – Artivion Institutional Activity
• Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates (Feb. 12), showing top‑line growth; this underpins the bull case but may already be priced in given prior analyst upgrades. MarketBeat – Artivion Earnings Summary
• Negative Sentiment: Multiple senior insiders sold shares on March 2 (CEO James Mackin sold ~14.9k shares; EVP Lance Berry and several SVPs also sold), a cluster of sales that markets often interpret as a negative signal even though insiders retain large holdings. See the SEC Form 4 for details. SEC Form 4 – Mackin

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.